See more : RCL Foods Limited (RCLFF) Income Statement Analysis – Financial Results
Complete financial analysis of Roche Holding AG (RHHBY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Roche Holding AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- ESPIRE HOSPITALITY LIMITED (ESPIRE.BO) Income Statement Analysis – Financial Results
- Industrial Tech Acquisitions II, Inc. (ITAQW) Income Statement Analysis – Financial Results
- Country Garden Holdings Company Limited (CTRYF) Income Statement Analysis – Financial Results
- Equus Total Return, Inc. (EQS) Income Statement Analysis – Financial Results
- All Ring Tech Co., Ltd. (6187.TWO) Income Statement Analysis – Financial Results
Roche Holding AG (RHHBY)
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.44B | 63.28B | 62.80B | 58.32B | 61.47B | 56.85B | 53.30B | 50.58B | 48.15B | 47.46B | 46.78B | 45.50B | 42.53B | 47.47B | 49.05B | 45.62B | 46.13B | 42.04B | 35.51B | 31.27B | 31.22B | 29.73B | 29.16B | 28.67B | 27.57B | 24.66B |
| Cost of Revenue | 16.36B | 20.40B | 19.65B | 16.18B | 18.35B | 17.27B | 18.18B | 16.18B | 15.46B | 13.38B | 11.95B | 12.18B | 11.94B | 13.29B | 14.62B | 13.66B | 13.74B | 10.62B | 9.30B | 7.18B | 8.32B | 8.43B | 8.34B | 9.16B | 8.87B | 7.90B |
| Gross Profit | 44.08B | 42.88B | 43.15B | 42.15B | 43.12B | 39.58B | 35.12B | 34.40B | 32.69B | 34.08B | 34.83B | 33.32B | 30.59B | 34.18B | 34.44B | 31.96B | 32.39B | 31.43B | 26.21B | 24.09B | 22.91B | 21.29B | 20.82B | 19.51B | 18.69B | 16.76B |
| Gross Profit Ratio | 72.94% | 67.77% | 68.72% | 72.26% | 70.14% | 69.62% | 65.89% | 68.01% | 67.89% | 71.81% | 74.46% | 73.24% | 71.92% | 72.00% | 70.20% | 70.05% | 70.21% | 74.75% | 73.80% | 77.03% | 73.37% | 71.63% | 71.41% | 68.04% | 67.81% | 67.96% |
| Research & Development | 14.20B | 16.02B | 14.80B | 13.01B | 12.77B | 12.09B | 11.29B | 11.53B | 9.58B | 9.90B | 9.27B | 9.55B | 8.33B | 10.03B | 9.87B | 8.85B | 8.39B | 6.59B | 5.71B | 5.09B | 4.77B | 4.26B | 3.89B | 3.95B | 3.78B | 3.41B |
| General & Administrative | 14.88B | 2.89B | 3.33B | 3.04B | 4.12B | 5.26B | 3.43B | 1.72B | 2.73B | 3.84B | 2.65B | 3.05B | 2.34B | 2.87B | 2.18B | 2.33B | 2.45B | 2.54B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Selling & Marketing | 0.00 | 9.64B | 9.92B | 9.57B | 10.96B | 10.11B | 9.85B | 9.14B | 8.81B | 8.66B | 8.37B | 8.54B | 8.05B | 9.49B | 9.48B | 9.17B | 9.33B | 10.86B | 9.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.88B | 12.53B | 13.25B | 12.61B | 15.08B | 15.37B | 13.27B | 10.86B | 11.54B | 12.50B | 11.02B | 11.59B | 10.39B | 12.36B | 11.65B | 11.50B | 11.78B | 13.40B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Other Expenses | -392.00M | -192.00M | -238.00M | -265.00M | -227.00M | -197.00M | -311.00M | -316.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.69B | 25.41B | 25.00B | 23.60B | 25.57B | 24.83B | 22.12B | 20.33B | 18.86B | 19.99B | 18.46B | 19.21B | 17.15B | 20.71B | 19.45B | 18.06B | 17.92B | 19.71B | 17.54B | 15.11B | 17.31B | 19.96B | 17.58B | 12.38B | 12.27B | 12.39B |
| Cost & Expenses | 45.05B | 45.81B | 44.65B | 39.78B | 43.92B | 42.10B | 40.30B | 36.51B | 34.32B | 33.37B | 30.40B | 31.39B | 29.09B | 34.01B | 34.06B | 31.72B | 31.67B | 30.33B | 26.84B | 22.29B | 25.63B | 28.39B | 25.92B | 21.54B | 21.15B | 20.29B |
| Interest Income | 183.00M | 67.00M | 342.00M | 16.00M | 99.00M | 30.00M | 30.00M | 22.00M | 24.00M | 34.00M | 27.00M | 32.00M | 73.00M | 51.00M | 179.00M | 698.00M | 1.07B | 788.00M | 423.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 997.00M | 690.00M | 419.00M | 553.00M | 791.00M | 744.00M | 765.00M | 958.00M | 1.11B | 1.18B | 1.33B | 2.00B | 2.01B | 2.55B | 2.44B | 214.00M | 281.00M | 315.00M | 264.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.46B | 3.82B | 4.45B | 4.57B | 4.31B | 3.60B | 3.89B | 3.95B | 3.64B | 2.62B | 2.38B | 2.42B | 2.37B | 2.55B | 2.69B | 2.65B | 2.54B | 2.44B | 1.01B | 1.61B | 1.51B | 1.52B | 1.55B | 2.85B | 2.45B | 2.07B |
| EBITDA | 18.54B | 20.86B | 22.86B | 23.08B | 21.70B | 22.51B | 21.19B | 17.91B | 16.74B | 19.13B | 18.99B | 16.24B | 16.29B | 16.27B | 15.50B | 16.48B | 18.12B | 15.34B | 9.68B | 10.58B | 7.10B | 2.86B | 4.80B | 27.57B | 8.87B | 6.44B |
| EBITDA Ratio | 30.67% | 34.02% | 36.40% | 38.58% | 35.37% | 31.95% | 31.52% | 35.38% | 35.44% | 35.03% | 39.76% | 37.30% | 38.48% | 34.69% | 37.52% | 36.12% | 37.31% | 33.97% | 27.26% | 33.84% | 22.75% | 9.60% | 16.46% | 34.80% | 32.19% | 26.13% |
| Operating Income | 15.40B | 17.48B | 18.16B | 18.54B | 17.55B | 14.77B | 13.00B | 14.07B | 13.82B | 14.09B | 16.38B | 14.13B | 13.45B | 13.49B | 12.28B | 13.92B | 14.47B | 11.73B | 8.67B | 8.98B | 5.59B | 1.34B | 3.25B | 7.13B | 6.42B | 4.37B |
| Operating Income Ratio | 25.47% | 27.62% | 28.91% | 31.79% | 28.55% | 25.98% | 24.40% | 27.82% | 28.71% | 29.69% | 35.01% | 31.04% | 31.63% | 28.41% | 25.03% | 30.52% | 31.36% | 27.90% | 24.41% | 28.71% | 17.91% | 4.49% | 11.13% | 24.87% | 23.29% | 17.72% |
| Total Other Income/Expenses | -1.32B | -1.15B | -757.00M | -578.00M | -934.00M | -621.00M | -755.00M | -1.06B | -1.83B | -1.58B | -1.70B | -1.97B | -1.57B | -2.28B | -2.05B | 237.00M | 836.00M | 857.00M | 133.00M | 506.00M | -711.00M | -4.53B | 1.52B | 2.34B | 1.13B | 1.08B |
| Income Before Tax | 14.08B | 16.33B | 17.40B | 17.97B | 16.61B | 14.15B | 12.25B | 13.01B | 11.99B | 12.52B | 14.68B | 12.32B | 11.89B | 11.21B | 10.23B | 14.16B | 15.30B | 12.59B | 8.97B | 9.49B | 4.88B | -3.19B | 4.76B | 9.47B | 7.56B | 5.45B |
| Income Before Tax Ratio | 23.29% | 25.80% | 27.70% | 30.80% | 27.03% | 24.89% | 22.98% | 25.72% | 24.90% | 26.37% | 31.37% | 27.08% | 27.94% | 23.62% | 20.86% | 31.04% | 33.17% | 29.94% | 25.25% | 30.33% | 15.63% | -10.75% | 16.33% | 33.02% | 27.41% | 22.11% |
| Income Tax Expense | 1.72B | 2.80B | 2.46B | 2.90B | 2.51B | 3.28B | 3.42B | 3.27B | 2.93B | 2.98B | 3.30B | 2.55B | 2.34B | 2.32B | 1.72B | 3.32B | 3.87B | 3.44B | 2.22B | 2.35B | 1.45B | 839.00M | 1.04B | 2.27B | 1.90B | 965.00M |
| Net Income | 11.50B | 12.42B | 13.93B | 14.30B | 13.50B | 10.50B | 8.63B | 9.58B | 8.86B | 9.33B | 11.16B | 9.43B | 9.34B | 8.67B | 7.78B | 8.97B | 9.76B | 7.88B | 5.92B | 6.61B | 3.07B | -4.03B | 3.70B | 8.65B | 5.76B | 4.39B |
| Net Income Ratio | 19.02% | 19.63% | 22.18% | 24.51% | 21.96% | 18.47% | 16.20% | 18.93% | 18.41% | 19.66% | 23.86% | 20.72% | 21.97% | 18.25% | 15.87% | 19.66% | 21.16% | 18.74% | 16.68% | 21.12% | 9.83% | -13.54% | 12.68% | 30.16% | 20.91% | 17.81% |
| EPS | 14.31 | 1.94 | 2.05 | 2.09 | 1.97 | 1.54 | 1.26 | 1.41 | 1.30 | 1.37 | 1.65 | 1.39 | 1.38 | 1.27 | 1.13 | 1.30 | 1.42 | 1.16 | 0.88 | 0.98 | 0.46 | -0.60 | 0.55 | 1.29 | 0.84 | 0.64 |
| EPS Diluted | 14.30 | 1.94 | 2.03 | 2.07 | 1.95 | 1.53 | 1.25 | 1.39 | 1.29 | 1.35 | 1.62 | 1.38 | 1.37 | 1.26 | 1.13 | 1.28 | 1.40 | 1.13 | 0.86 | 0.97 | 0.45 | -0.60 | 0.55 | 1.28 | 0.84 | 0.64 |
| Weighted Avg Shares Out | 803.49M | 6.40B | 6.80B | 6.84B | 6.85B | 6.83B | 6.82B | 6.82B | 6.81B | 6.79B | 6.78B | 6.78B | 6.79B | 6.84B | 6.86B | 6.88B | 6.87B | 6.82B | 6.76B | 6.72B | 6.71B | 6.71B | 6.72B | 6.72B | 6.90B | 6.90B |
| Weighted Avg Shares Out (Dil) | 804.00M | 6.40B | 6.88B | 6.92B | 6.91B | 6.88B | 6.88B | 6.88B | 6.90B | 6.90B | 6.90B | 6.84B | 6.81B | 6.86B | 6.87B | 6.89B | 6.90B | 6.90B | 6.88B | 6.80B | 6.80B | 6.71B | 6.90B | 6.76B | 6.90B | 6.90B |
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
Roche Setback Is Big for Eli Lilly, Novo Nordisk as Obesity Drug Battle Ramps Up
The company's stock was falling after a report detailing side effects from its once-daily weight-loss pill.
Roche shares drop on side effects result in early-stage obesity pill trial
Shares in Roche fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans.
Why Roche Holdings Stock Withered on Wednesday
The storied European pharmaceutical is forging ahead in its efforts to develop a weight loss treatment. Recent news from the lab about the medication is not encouraging, however.
Roche says early-stage obesity pill results were based on just six patients
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety Data
Roche stock has risen 22% since May due to promising GLP-1 agonist drug candidates, despite recent setbacks with CT-388's side effects. Roche's GLP-1 pipeline includes CT-388, CT-996 and CT-868, aiming to compete with Lilly and Novo's blockbuster weight loss drugs....
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the opening of its new Pharma Research and Early Development (pRED) Center at its global headquarters in Basel, Switzerland. Equipped with cutting-edge technologies and housing around 1,000...
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing
Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea , Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions...
The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVE
Amazon, Roche, GE Aerospace, Canterbury Park and NVE are included in this Analyst Blog.
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics
Stratipath, a global leader in artificial intelligence (AI)-based precision diagnostic solutions, is thrilled to announce a collaboration with Roche, the world's largest biotechnology company and the global leader in in-vitro diagnostics. In this non-exclusive collaboration, Roche will have the distribution...
Source: https://incomestatements.info
Category: Stock Reports